Auro Laboratories Ltd.
BSE: AUROLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Auro Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Auro Laboratories Limited is a Mumbai-based pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs). The company focuses primarily on anti-diabetic drugs, with Metformin Hydrochloride as its flagship product, alongside the production of intermediates and specialty chemicals.
Business Model
The company generates revenue through the cost-effective bulk production of APIs and chemical intermediates for both domestic and international markets. It leverages a GMP-compliant manufacturing facility in Tarapur to maintain regulatory standards required for global exports.
- Primary Product:Metformin Hydrochloride
- Manufacturing Location:Tarapur, Maharashtra
Growth Outlook
Growth is driven by the company's focus on maintaining a lean operational structure and ensuring regulatory compliance to expand its footprint in international markets including Southeast Asia, the Middle East, and Africa.
Key Risks
- Regulatory Compliance Risk. Failure to maintain Good Manufacturing Practices could lead to the loss of export licenses and market access.
- Concentration Risk. Heavy reliance on a single flagship product, Metformin Hydrochloride, exposes the company to market volatility in the anti-diabetic segment.
- Input Cost Volatility. Fluctuations in the prices of raw materials and chemical intermediates can significantly impact profit margins for bulk drug manufacturers.
- Competitive Pressure. As a small-cap entity, the company faces intense competition from larger pharmaceutical firms with greater economies of scale.
Start your research today
Unlock AI insights, financials, peers and live data on Auro Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹31 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹6.01
TTM · standalone
RETURN ON EQUITY
8.6%
TTM · standalone
P/E
39.5x
Q4 FY26 · standalone
EV/EBITDA
19.1x
Q4 FY26 · standalone
EBITDA MARGIN
39.6%
TTM · standalone
NET PROFIT MARGIN
9.9%
Q4 FY26 · standalone
DEBT TO EQUITY
1.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Auro Laboratories Ltd.AUROLAB | ₹145 Cr | 38.64 | 16.91 | 60.0% | 39.6% | 8.6% | 11.4% | +12.1% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Auro Laboratories Ltd.
BSE: AUROLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Auro Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Auro Laboratories Limited is a Mumbai-based pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs). The company focuses primarily on anti-diabetic drugs, with Metformin Hydrochloride as its flagship product, alongside the production of intermediates and specialty chemicals.
Business Model
The company generates revenue through the cost-effective bulk production of APIs and chemical intermediates for both domestic and international markets. It leverages a GMP-compliant manufacturing facility in Tarapur to maintain regulatory standards required for global exports.
- Primary Product:Metformin Hydrochloride
- Manufacturing Location:Tarapur, Maharashtra
Growth Outlook
Growth is driven by the company's focus on maintaining a lean operational structure and ensuring regulatory compliance to expand its footprint in international markets including Southeast Asia, the Middle East, and Africa.
Key Risks
- Regulatory Compliance Risk. Failure to maintain Good Manufacturing Practices could lead to the loss of export licenses and market access.
- Concentration Risk. Heavy reliance on a single flagship product, Metformin Hydrochloride, exposes the company to market volatility in the anti-diabetic segment.
- Input Cost Volatility. Fluctuations in the prices of raw materials and chemical intermediates can significantly impact profit margins for bulk drug manufacturers.
- Competitive Pressure. As a small-cap entity, the company faces intense competition from larger pharmaceutical firms with greater economies of scale.
Start your research today
Unlock AI insights, financials, peers and live data on Auro Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹31 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹6.01
TTM · standalone
RETURN ON EQUITY
8.6%
TTM · standalone
P/E
39.5x
Q4 FY26 · standalone
EV/EBITDA
19.1x
Q4 FY26 · standalone
EBITDA MARGIN
39.6%
TTM · standalone
NET PROFIT MARGIN
9.9%
Q4 FY26 · standalone
DEBT TO EQUITY
1.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26